{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:16:35Z","timestamp":1793146595115,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Finalizzata Giovani Ricercatori-GR-2021-12374957"],"award-info":[{"award-number":["Ricerca Finalizzata Giovani Ricercatori-GR-2021-12374957"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG2025 #30515"],"award-info":[{"award-number":["IG2025 #30515"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG2021 #25766"],"award-info":[{"award-number":["IG2021 #25766"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG2023 #29259"],"award-info":[{"award-number":["IG2023 #29259"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["Programma di Ricerca 5 per Mille 2018 grant Id:21073"],"award-info":[{"award-number":["Programma di Ricerca 5 per Mille 2018 grant Id:21073"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["MFAG2021 #26004"],"award-info":[{"award-number":["MFAG2021 #26004"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondo di Beneficenza Intesa SanPaolo","award":["grant Id:B\/2024\/0194 NAMPT"],"award-info":[{"award-number":["grant Id:B\/2024\/0194 NAMPT"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic cutaneous melanoma (MCM) is primarily treated with BRAF\/MEK inhibitors and immune checkpoint inhibitors (ICIs), but the long-term efficacy of these therapies is often limited by acquired resistance. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD biosynthesis, is frequently upregulated in MCM, supporting metabolic rewiring and targeted therapy resistance.<\/jats:p>\n                    <jats:p>Interferon-\u03b3 (IFN-\u03b3) signaling plays a central role in melanoma biology, exerting both antitumor and immunoregulatory effects, linked with the onset of therapeutic resistance. Emerging evidence suggests that metabolic pathways may critically modulate IFN-\u03b3 responses; however, the functional interplay between NAD\/NAMPT metabolism and IFN-\u03b3 signaling in melanoma cells remains poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated transcriptomic, bioinformatic, biochemical, and functional approaches in human and murine melanoma cell lines, together with analyses of TCGA datasets and a tissue microarray (TMA) cohort. Mechanistic studies included pharmacological and genetic perturbation of Bromodomain and Extra-Terminal motif (BET) epigenetic factor BRD4, Interferon Regulatory Factor 1 (IRF1), and NAMPT, chromatin immunoprecipitation (ChIP) assays, and metabolic analyses. Tumor-T cell co-culture systems were used to assess the impact of melanoma-cell NAMPT modulation on T-cell behavior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IFN-\u03b3 induced NAMPT expression through a BRD4\/IRF1-dependent transcriptional program. In turn, NAMPT activity was required to sustain IFN-\u03b3 signaling, as its inhibition impaired STAT1 activation and downstream transcriptional responses. Mechanistically, NAMPT-dependent NAD metabolism supported mitochondrial complex I activity and oxidative metabolism and was required for efficient BRD4 recruitment to IFN-responsive promoters, including CD274\/PD-L1 and NAMPT itself. Across melanoma datasets and patient samples, NAMPT expression correlated with IFN-\u03b3\u2013responsive genes, including PD-L1. Functionally, modulation of NAMPT in melanoma cells influenced T-cell cytotoxicity and migration in co-culture systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, these findings identify NAMPT as a key metabolic component of the IFN-\u03b3 response network in melanoma cells, establishing a feed-forward regulatory circuit linking cytokine signaling, chromatin regulation, and mitochondrial metabolism. This work provides a framework to investigate how metabolic control of IFN-\u03b3 signaling shapes tumor-immune interactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03734-2","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:56:46Z","timestamp":1778745406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bi-directional regulation between NAD\/NAMPT and IFN-\u03b3\/PD-L1 axes via BRD4\/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Irene","family":"Fiorilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ponzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Moiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Riccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Avalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Carr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ugolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Calussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Maria","family":"Todesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Digiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Casone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ponzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Szumera-Cie\u0107kiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cavaletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Ettore","family":"Porporato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Massi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Calautti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Audrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"3734_CR1","doi-asserted-by":"publisher","unstructured":"Wawrzyniak P, Hartman ML. Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors. Mol Cancer. 2025;24(1). https:\/\/doi.org\/10.1186\/S12943-025-02294-X. PMID: 40108693.","DOI":"10.1186\/S12943-025-02294-X"},{"issue":"9","key":"3734_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/S41571-019-0204-6","volume":"16","author":"X Bai","year":"2019","unstructured":"Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFN\u03b3 pathways. Nat Rev Clin Oncol. 2019;16(9):549\u201362. https:\/\/doi.org\/10.1038\/S41571-019-0204-6. PMID: 30967646.","journal-title":"Nat Rev Clin Oncol. 2019;"},{"key":"3734_CR3","doi-asserted-by":"publisher","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C et al. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell. 2016;167(6):1540\u20131554.e12. https:\/\/doi.org\/10.1016\/j.cell.2016.11.022. PMID: 27912061.","DOI":"10.1016\/j.cell.2016.11.022"},{"key":"3734_CR4","doi-asserted-by":"publisher","unstructured":"Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. Biomedicines. 2021;9(7). https:\/\/doi.org\/10.3390\/BIOMEDICINES9070835. PMID: 34356899.","DOI":"10.3390\/BIOMEDICINES9070835"},{"key":"3734_CR5","doi-asserted-by":"publisher","unstructured":"Flaherty KT, Aplin AE, Davies MA, Hacohen N, Herlyn M, Hoon D et al. Facts and Hopes: Toward the Next Quantum Leap in Melanoma. Clin Cancer Res. 2025;31(14):2882\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0278. PMID: 40407722.","DOI":"10.1158\/1078-0432.CCR-25-0278"},{"key":"3734_CR6","doi-asserted-by":"publisher","unstructured":"Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19(7):377\u201391. https:\/\/doi.org\/10.1038\/S41568-019-0154-4. PMID: 31209265.","DOI":"10.1038\/S41568-019-0154-4"},{"key":"3734_CR7","doi-asserted-by":"publisher","unstructured":"Fateeva A, Eddy K, Chen S. Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance. Cancers (Basel). 2024;16(8). https:\/\/doi.org\/10.3390\/CANCERS16081571. PMID: 38672652.","DOI":"10.3390\/CANCERS16081571"},{"key":"3734_CR8","doi-asserted-by":"publisher","unstructured":"Jalil A, Donate MM, Mattei J. Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. Cancer Drug Resist. 2024;7. https:\/\/doi.org\/10.20517\/CDR.2024.54. PMID: 39534873.","DOI":"10.20517\/CDR.2024.54"},{"key":"3734_CR9","doi-asserted-by":"publisher","unstructured":"Gasparrini M, Audrito V, NAMPT. A critical driver and therapeutic target for cancer. Int J Biochem Cell Biol. 2022;145. https:\/\/doi.org\/10.1016\/J.BIOCEL.2022.106189. PMID: 35219878.","DOI":"10.1016\/J.BIOCEL.2022.106189"},{"key":"3734_CR10","doi-asserted-by":"publisher","unstructured":"Semerena E, Nencioni A, Masternak K. Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/FIMMU.2023.1268756. PMID: 37915565.","DOI":"10.3389\/FIMMU.2023.1268756"},{"key":"3734_CR11","doi-asserted-by":"publisher","unstructured":"Katsyuba E, Romani M, Hofer D, Auwerx J. NAD+ homeostasis in health and disease. Nat Metab. 2020;2(1):9\u201331. https:\/\/doi.org\/10.1038\/S42255-019-0161-5. PMID: 32694684.","DOI":"10.1038\/S42255-019-0161-5"},{"key":"3734_CR12","doi-asserted-by":"publisher","unstructured":"Audrito V, Messana VG, Deaglio S. NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/FONC.2020.00358. PMID: 32266141.","DOI":"10.3389\/FONC.2020.00358"},{"key":"3734_CR13","doi-asserted-by":"publisher","unstructured":"Audrito V, Manag\u00f2 A, Gaudino F, Deaglio S. Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). Semin Cell Dev Biol. 2020;98:192\u2013201. https:\/\/doi.org\/10.1016\/J.SEMCDB.2019.05.001 PMID: 31059816.","DOI":"10.1016\/J.SEMCDB.2019.05.001"},{"key":"3734_CR14","doi-asserted-by":"publisher","unstructured":"Audrito V, Manag\u00f2 A, La Vecchia S, Zamporlini F, Vitale N, Baroni G et al. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. J Natl Cancer Inst. 2018;110(3). https:\/\/doi.org\/10.1093\/JNCI\/DJX198. PMID: 29309612.","DOI":"10.1093\/JNCI\/DJX198"},{"key":"3734_CR15","doi-asserted-by":"publisher","unstructured":"Audrito V, Manag\u00f2 A, Zamporlini F, Rulli E, Gaudino F, Madonna G et al. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. Oncotarget. 2018;9(27):18997\u20139005. https:\/\/doi.org\/10.18632\/ONCOTARGET.24871. PMID: 29721178.","DOI":"10.18632\/ONCOTARGET.24871"},{"key":"3734_CR16","doi-asserted-by":"publisher","unstructured":"Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G et al. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev. 2018;32(5\u20136):448\u201361. https:\/\/doi.org\/10.1101\/GAD.305854.117. PMID: 29567766.","DOI":"10.1101\/GAD.305854.117"},{"key":"3734_CR17","doi-asserted-by":"publisher","unstructured":"Ghezzi B, Fiorilla I, Carreira \u00c1, Recco F, Sorci L, Avalle L et al. NAMPT and NNMT released via extracellular vesicles and as soluble mediators are distinguished traits of BRAF inhibitor resistance of melanoma cells impacting on the tumor microenvironment. Cell Commun Signal. 2025;23(1). https:\/\/doi.org\/10.1186\/S12964-025-02361-2. PMID: 40691620.","DOI":"10.1186\/S12964-025-02361-2"},{"key":"3734_CR18","doi-asserted-by":"publisher","unstructured":"Chini CCS, Zeidler JD, Kashyap S, Warner G, Chini EN. Evolving concepts in NAD+ metabolism. Cell Metab. 2021;33(6):1076\u201387. https:\/\/doi.org\/10.1016\/j.cmet.2021.04.003. PMID: 33930322.","DOI":"10.1016\/j.cmet.2021.04.003"},{"key":"3734_CR19","doi-asserted-by":"publisher","unstructured":"Yusri K, Jose S, Vermeulen KS, Tan TCM, Sorrentino V. The role of NAD+ metabolism and its modulation of mitochondria in aging and disease. npj metabolic health and disease. 2025;3(1). https:\/\/doi.org\/10.1038\/S44324-025-00067-0. PMID: 40604314.","DOI":"10.1038\/S44324-025-00067-0"},{"key":"3734_CR20","doi-asserted-by":"publisher","unstructured":"Brenner C. Viral infection as an NAD+ battlefield. Nat Metab. 2022;4(1):2\u20133. https:\/\/doi.org\/10.1038\/S42255-021-00507-3. PMID: 34980922.","DOI":"10.1038\/S42255-021-00507-3"},{"key":"3734_CR21","doi-asserted-by":"publisher","unstructured":"Billingham LK, Chandel NS. NAD-biosynthetic pathways regulate innate immunity. Nat Immunol. 2019;20(4):380\u20132. https:\/\/doi.org\/10.1038\/S41590-019-0353-X. PMID: 30858621.","DOI":"10.1038\/S41590-019-0353-X"},{"issue":"1","key":"3734_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12950-025-00457-7","volume":"22","author":"R Mann","year":"2025","unstructured":"Mann R, Stavrou V, Dimeloe S. NAD\u2009+\u2009metabolism and function in innate and adaptive immune cells. J Inflamm 2025. 2025;22(1):1. https:\/\/doi.org\/10.1186\/S12950-025-00457-7.","journal-title":"J Inflamm 2025"},{"key":"3734_CR23","doi-asserted-by":"publisher","unstructured":"Kiritsy MC, McCann K, Mott D, Holland SM, Behar SM, Sassetti CM et al. Mitochondrial respiration contributes to the interferon gamma response in antigen-presenting cells. Elife. 2021;10. https:\/\/doi.org\/10.7554\/ELIFE.65109. PMID: 34726598.","DOI":"10.7554\/ELIFE.65109"},{"key":"3734_CR24","doi-asserted-by":"publisher","unstructured":"Tsai CH, Chuang YM, Li X, Yu YR, Tzeng SF, Teoh ST et al. Immunoediting instructs tumor metabolic reprogramming to support immune evasion. Cell Metab. 2023;35(1):118\u2013133.e7. https:\/\/doi.org\/10.1016\/j.cmet.2022.12.003. PMID: 36599297.","DOI":"10.1016\/j.cmet.2022.12.003"},{"key":"3734_CR25","doi-asserted-by":"publisher","unstructured":"McCann KJ, Christensen SM, Colby DH, McGuire PJ, Myles IA, Zerbe CS et al. IFN\u03b3 regulates NAD+ metabolism to promote the respiratory burst in human monocytes. Blood Adv. 2022;6(12):3821\u201334. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2021005776. PMID: 35500221.","DOI":"10.1182\/BLOODADVANCES.2021005776"},{"key":"3734_CR26","doi-asserted-by":"publisher","unstructured":"Huffaker TB, Ekiz HA, Barba C, Lee SH, Runtsch MC, Nelson MC et al. A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages. Nat Commun. 2021;12(1). https:\/\/doi.org\/10.1038\/S41467-021-22923-5. PMID: 33976173.","DOI":"10.1038\/S41467-021-22923-5"},{"key":"3734_CR27","doi-asserted-by":"publisher","unstructured":"Chen KC, Dhar T, Chen CR, Chen ECY, Peng CC. Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024;1870(4):167106. https:\/\/doi.org\/10.1016\/J.BBADIS.2024.167106. PMID: 38428685.","DOI":"10.1016\/J.BBADIS.2024.167106"},{"key":"3734_CR28","doi-asserted-by":"publisher","unstructured":"Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metab. 2021;33(1):110\u2013127.e5. https:\/\/doi.org\/10.1016\/j.cmet.2020.10.021. PMID: 33171124.","DOI":"10.1016\/j.cmet.2020.10.021"},{"key":"3734_CR29","doi-asserted-by":"publisher","unstructured":"Moore AM, Zhou L, Cui J, Li L, Wu N, Yu A et al. NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Proc Natl Acad Sci U S A. 2021;118(8):e2012469118. https:\/\/doi.org\/10.1073\/PNAS.2012469118\/SUPPL_FILE\/PNAS.2012469118.SM02.MOV. PMID: 33597293.","DOI":"10.1073\/PNAS.2012469118\/SUPPL_FILE\/PNAS.2012469118.SM02.MOV"},{"key":"3734_CR30","doi-asserted-by":"publisher","unstructured":"Barba C, Ekiz HA, Tang WW, Ghazaryan A, Hansen M, Lee SH et al. Interferon Gamma-Inducible NAMPT in Melanoma Cells Serves as a Mechanism of Resistance to Enhance Tumor Growth. Cancers (Basel). 2023;15(5). https:\/\/doi.org\/10.3390\/CANCERS15051411. PMID: 36900204.","DOI":"10.3390\/CANCERS15051411"},{"key":"3734_CR31","doi-asserted-by":"publisher","unstructured":"Ponzone L, Audrito V, Landi C, Moiso E, Levra Levron C, Ferrua S et al. RICTOR\/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF\/MEK inhibition. Mol Cancer. 2024;23(1). https:\/\/doi.org\/10.1186\/S12943-024-02010-1. PMID: 38755661.","DOI":"10.1186\/S12943-024-02010-1"},{"key":"3734_CR32","doi-asserted-by":"publisher","unstructured":"Audrito V, Moiso E, Ugolini F, Messana VG, Brandimarte L, Manfredonia I et al. Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties. J Transl Med. 2022;20(1):1\u201313. https:\/\/doi.org\/10.1186\/S12967-022-03315-9\/FIGURES\/7. PMID: 35272691.","DOI":"10.1186\/S12967-022-03315-9\/FIGURES\/7"},{"key":"3734_CR33","doi-asserted-by":"publisher","unstructured":"Audrito V, Messana VG, Moiso E, Vitale N, Arruga F, Brandimarte L et al. NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. Cancers (Basel). 2020;12(12):1\u201322. https:\/\/doi.org\/10.3390\/CANCERS12123855. PMID: 33419372.","DOI":"10.3390\/CANCERS12123855"},{"key":"3734_CR34","doi-asserted-by":"publisher","unstructured":"Ebine K, Kumar K, Pham TN, Shields MA, Collier KA, Shang M et al. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells. Sci Rep. 2018;8(1):1\u201311. https:\/\/doi.org\/10.1038\/S41598-018-31658-1; TECHMETA. PMID: 30185888.","DOI":"10.1038\/S41598-018-31658-1"},{"key":"3734_CR35","doi-asserted-by":"publisher","unstructured":"Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA et al. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep. 2017;18(9):2162\u201374. https:\/\/doi.org\/10.1016\/J.CELREP.2017.02.011. PMID: 28249162.","DOI":"10.1016\/J.CELREP.2017.02.011"},{"issue":"4","key":"3734_CR36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/S41417-025-00891-Y","volume":"32","author":"M Kanduri","year":"2025","unstructured":"Kanduri M, Subhash S, Putino R, Mahale S, Kanduri C. IER3: exploring its dual function as an oncogene and tumor suppressor. Cancer Gene Ther. 2025;32(4):450\u201363. https:\/\/doi.org\/10.1038\/S41417-025-00891-Y .TECHMETA. PMID: 40090972.","journal-title":"Cancer Gene Ther"},{"key":"3734_CR37","doi-asserted-by":"publisher","unstructured":"Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52(D1):D174\u201382. https:\/\/doi.org\/10.1093\/NAR\/GKAD1059. PMID: 37962376.","DOI":"10.1093\/NAR\/GKAD1059"},{"key":"3734_CR38","doi-asserted-by":"publisher","unstructured":"Tarone L, Giacobino D, Camerino M, Maniscalco L, Iussich S, Parisi L et al. A chimeric human\/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma. Molecular Therapy. 2023;31(8):2342\u201359. https:\/\/doi.org\/10.1016\/j.ymthe.2023.06.004. PMID: 37312451.","DOI":"10.1016\/j.ymthe.2023.06.004"},{"key":"3734_CR39","doi-asserted-by":"publisher","unstructured":"Tseng HW, Li SC, Tsai KW. Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression. Cancers (Basel). 2019;11(2). https:\/\/doi.org\/10.3390\/CANCERS11020209. PMID: 30754729.","DOI":"10.3390\/CANCERS11020209"},{"key":"3734_CR40","doi-asserted-by":"publisher","unstructured":"Salaroglio IC, Belisario DC, Akman M, La Vecchia S, Godel M, Anobile DP et al. Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer. J Exp Clin Cancer Res. 2022;41(1):243. https:\/\/doi.org\/10.1186\/S13046-022-02447-6. PMID: 35953814.","DOI":"10.1186\/S13046-022-02447-6"},{"key":"3734_CR41","doi-asserted-by":"publisher","unstructured":"Xu X, Tassone B, Ostano P, Katarkar A, Proust T, Joseph J et al. HSD17B7 gene in self-renewal and oncogenicity of keratinocytes from Black versus White populations. EMBO Mol Med. 2021;13(7). https:\/\/doi.org\/10.15252\/EMMM.202114133. PMID: 34185380.","DOI":"10.15252\/EMMM.202114133"},{"key":"3734_CR42","doi-asserted-by":"publisher","unstructured":"Jain S, Hu C, Kluza J, Ke W, Tian G, Giurgiu M et al. Metabolic targeting of cancer by a ubiquinone uncompetitive inhibitor of mitochondrial complex I. Cell Chem Biol. 2022;29(3):436\u2013450.e15. https:\/\/doi.org\/10.1016\/j.chembiol.2021.11.002. PMID: 34852219.","DOI":"10.1016\/j.chembiol.2021.11.002"},{"key":"3734_CR43","doi-asserted-by":"publisher","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603\u20137. https:\/\/doi.org\/10.1038\/NATURE11003. PMID: 22460905.","DOI":"10.1038\/NATURE11003"},{"key":"3734_CR44","doi-asserted-by":"publisher","unstructured":"Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 2009;37(Database issue). https:\/\/doi.org\/10.1093\/NAR\/GKN653. PMID: 18832364.","DOI":"10.1093\/NAR\/GKN653"},{"key":"3734_CR45","doi-asserted-by":"publisher","unstructured":"Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M et al. Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020;38(4):500\u2013515.e3. https:\/\/doi.org\/10.1016\/J.CCELL.2020.08.005. PMID: 32916126.","DOI":"10.1016\/J.CCELL.2020.08.005"},{"key":"3734_CR46","doi-asserted-by":"publisher","unstructured":"Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A et al. Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non\u2013Small Cell Lung Cancer. Clinical Cancer Research. 2025;31(12):2413\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2990\/761274\/P\/FACTORS-ASSOCIATED-WITH-DISEASE-PROGRESSION-AFTER. PMID: 40247431.","DOI":"10.1158\/1078-0432.CCR-24-2990\/761274\/P\/FACTORS-ASSOCIATED-WITH-DISEASE-PROGRESSION-AFTER"},{"key":"3734_CR47","doi-asserted-by":"publisher","unstructured":"Colombo G, Travelli C, Porta C, Genazzani AA. Extracellular nicotinamide phosphoribosyltransferase boosts IFN\u03b3-induced macrophage polarization independently of TLR4. iScience. 2022;25(4):104147. https:\/\/doi.org\/10.1016\/J.ISCI.2022.104147. PMID: 35402885.","DOI":"10.1016\/J.ISCI.2022.104147"},{"key":"3734_CR48","doi-asserted-by":"publisher","unstructured":"Lee LYH, Oldham WM, He H, Wang R, Mulhern R, Handy DE et al. Interferon-\u03b3 Impairs Human Coronary Artery Endothelial Glucose Metabolism by Tryptophan Catabolism and Activates Fatty Acid Oxidation. Circulation. 2021;144(20):1612\u201328. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.053960. PMID: 34636650.","DOI":"10.1161\/CIRCULATIONAHA.121.053960"},{"key":"3734_CR49","doi-asserted-by":"publisher","unstructured":"Yao J, Gan W, Sun J, Han Z, Li D, Cao L et al. APOL6 as a potential biomarker of immuno-correlation and therapeutic prediction in cancer immunotherapy. Medicine. 2025;104(19):e42406. https:\/\/doi.org\/10.1097\/MD.0000000000042406. PMID: 40355224.","DOI":"10.1097\/MD.0000000000042406"},{"key":"3734_CR50","doi-asserted-by":"publisher","unstructured":"Cheon HJ, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A. 2009;106(23):9373\u20138. https:\/\/doi.org\/10.1073\/PNAS.0903487106. PMID: 19478064.","DOI":"10.1073\/PNAS.0903487106"},{"key":"3734_CR51","doi-asserted-by":"publisher","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333. https:\/\/doi.org\/10.1016\/j.molmed.2014.10.009. PMID: 25440090.","DOI":"10.1016\/j.molmed.2014.10.009"},{"key":"3734_CR52","doi-asserted-by":"publisher","unstructured":"Jing X, Shao S, Zhang Y, Luo A, Zhao L, Zhang L et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer. Exp Cell Res. 2020;392(2):112034. https:\/\/doi.org\/10.1016\/J.YEXCR.2020.112034. PMID: 32339606.","DOI":"10.1016\/J.YEXCR.2020.112034"},{"key":"3734_CR53","doi-asserted-by":"publisher","unstructured":"Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ et al. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Rep. 2016;16(11):2829\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2016.08.032. PMID: 27626654.","DOI":"10.1016\/j.celrep.2016.08.032"},{"key":"3734_CR54","doi-asserted-by":"publisher","unstructured":"Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012;12(7):465\u201377. https:\/\/doi.org\/10.1038\/NRC3256;SUBJMETA. PMID: 22722403.","DOI":"10.1038\/NRC3256;SUBJMETA"},{"key":"3734_CR55","doi-asserted-by":"publisher","unstructured":"Donati B, Lorenzini E, Ciarrocchi A. BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17(1). https:\/\/doi.org\/10.1186\/S12943-018-0915-9. PMID: 30466442.","DOI":"10.1186\/S12943-018-0915-9"},{"key":"3734_CR56","doi-asserted-by":"publisher","unstructured":"Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013;73(20):6264\u201376. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0122-T. PMID: 23950209.","DOI":"10.1158\/0008-5472.CAN-13-0122-T"},{"key":"3734_CR57","doi-asserted-by":"publisher","unstructured":"Jiang G, Deng W, Liu Y, Wang C. General mechanism of JQ1 in inhibiting various types of cancer. Mol Med Rep. 2020;21(3):1021\u201334. https:\/\/doi.org\/10.3892\/MMR.2020.10927. PMID: 31922235.","DOI":"10.3892\/MMR.2020.10927"},{"key":"3734_CR58","doi-asserted-by":"publisher","unstructured":"Liu K, Zhou Z, Gao H, Yang F, Qian Y, Jin H et al. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression. Cell Biol Int. 2019;43(6):642\u201350. https:\/\/doi.org\/10.1002\/CBIN.11139. PMID: 30958600.","DOI":"10.1002\/CBIN.11139"},{"key":"3734_CR59","doi-asserted-by":"publisher","unstructured":"Zhang P, Li R, Xiao H, Liu W, Zeng X, Xie G et al. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor. Int J Biol Sci. 2019;15(9):1942. https:\/\/doi.org\/10.7150\/IJBS.34162. PMID: 31523195.","DOI":"10.7150\/IJBS.34162"},{"key":"3734_CR60","doi-asserted-by":"publisher","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29(1):115\u201326. https:\/\/doi.org\/10.1038\/S41591-022-02103-8. PMID: 36658425.","DOI":"10.1038\/S41591-022-02103-8"},{"issue":"5","key":"3734_CR61","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/J.MOLCEL.2016.02.011","volume":"61","author":"WX Zong","year":"2016","unstructured":"Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. Mol Cell. 2016;61(5):667\u201376. https:\/\/doi.org\/10.1016\/J.MOLCEL.2016.02.011. PMID: 26942671.","journal-title":"Mol Cell"},{"key":"3734_CR62","doi-asserted-by":"publisher","unstructured":"Kodiha M, Stochaj U. Nuclear transport: a switch for the oxidative stress-signaling circuit? J Signal Transduct. 2012;2012:1\u201318. https:\/\/doi.org\/10.1155\/2012\/208650. PMID: 22028962.","DOI":"10.1155\/2012\/208650"},{"issue":"8","key":"3734_CR63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1096\/FBA.2024-00078","volume":"6","author":"JX Huang","year":"2024","unstructured":"Huang JX, Wang CI, Kuo CY, Chang TW, Liu YC, Hsiao TF, et al. Oxidative stress mediates nucleocytoplasmic shuttling of KPNA2 via AKT1-CDK1 axis-regulated S62 phosphorylation. FASEB Bioadv. 2024;6(8):276\u201388. https:\/\/doi.org\/10.1096\/FBA.2024-00078.","journal-title":"FASEB Bioadv"},{"key":"3734_CR64","doi-asserted-by":"publisher","unstructured":"Kodiha M, Azad N, Chu S, Crampton N, Stochaj U. Oxidative stress and signaling through EGFR and PKA pathways converge on the nuclear transport factor RanBP1. Eur J Cell Biol. 2024;103(1):151376. https:\/\/doi.org\/10.1016\/J.EJCB.2023.151376. PMID: 38011756.","DOI":"10.1016\/J.EJCB.2023.151376"},{"key":"3734_CR65","doi-asserted-by":"publisher","unstructured":"XIE W, HUANG W, CAI S, CHEN H, FU W, CHEN Z et al. NF-\u03baB\/I\u03baB\u03b1 signaling pathways are essential for resistance to heat stress-induced ROS production in pulmonary microvascular endothelial cells. Mol Med Rep. 2021;24(5). https:\/\/doi.org\/10.3892\/MMR.2021.12454\/ABSTRACT. PMID: 34558646.","DOI":"10.3892\/MMR.2021.12454\/ABSTRACT"},{"key":"3734_CR66","doi-asserted-by":"publisher","unstructured":"Fontaine E, Metformin-Induced Mitochondrial Complex I, Inhibition. Facts, Uncertainties, and Consequences. Front Endocrinol (Lausanne). 2018;9. https:\/\/doi.org\/10.3389\/FENDO.2018.00753. PMID: 30619086.","DOI":"10.3389\/FENDO.2018.00753"},{"key":"3734_CR67","doi-asserted-by":"publisher","unstructured":"Reczek CR, Chakrabarty RP, D\u2019Alessandro KB, Sebo ZL, Grant RA, Gao P et al. Metformin targets mitochondrial complex I to lower blood glucose levels. Sci Adv. 2024;10(51):5466. https:\/\/doi.org\/10.1126\/SCIADV.ADS5466. PMID: 39693440.","DOI":"10.1126\/SCIADV.ADS5466"},{"key":"3734_CR68","doi-asserted-by":"publisher","unstructured":"Zhang Q, Shu DY, Bryan RA, Han JYS, Gulette GA, Lo K et al. Long-term Monitoring of Oxygen Consumption Rates in Highly Differentiated and Polarized Retinal Pigment Epithelial Cultures. J Vis Exp. 2024;2024-August(210). https:\/\/doi.org\/10.3791\/67038. PMID: 39221933.","DOI":"10.3791\/67038"},{"key":"3734_CR69","doi-asserted-by":"publisher","unstructured":"Le Poole IC, Riker AI, Quevedo ME, Stennett LS, Wang E, Marincola FM et al. Interferon-\u03b3 reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. American Journal of Pathology. 2002;160(2):521\u20138. https:\/\/doi.org\/10.1016\/S0002-9440(10)64871-7. PMID: 11839572.","DOI":"10.1016\/S0002-9440(10)64871-7"},{"key":"3734_CR70","doi-asserted-by":"publisher","unstructured":"Johnson RMG, Wen T, Dong H. Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nat Immunol. 2020;21(4):365\u20136. https:\/\/doi.org\/10.1038\/S41590-020-0599-3. PMID: 32152507.","DOI":"10.1038\/S41590-020-0599-3"},{"issue":"23","key":"3734_CR71","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.3390\/CANCERS17233803\/S1","volume":"17","author":"B Pell","year":"2025","unstructured":"Pell B, Kalizhanova A, Tursynkozha A, Dengi D, Kashkynbayev A, Kuang Y. Dynamic PD-L1 Regulation Shapes Tumor Immune Escape and Response to Immunotherapy. Cancers (Basel). 2025;17(23):3803. https:\/\/doi.org\/10.3390\/CANCERS17233803\/S1.","journal-title":"Cancers (Basel)"},{"key":"3734_CR72","doi-asserted-by":"publisher","unstructured":"Yadollahi P, Jeon YK, Ng WL, Choi I. Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity. BMB Rep. 2021;54(1):12. https:\/\/doi.org\/10.5483\/BMBREP.2021.54.1.241. PMID: 33298250.","DOI":"10.5483\/BMBREP.2021.54.1.241"},{"key":"3734_CR73","doi-asserted-by":"publisher","unstructured":"Beck L, Harel M, Yu S, Markovits E, Boursi B, Markel G et al. Clinical proteomics of metastatic melanoma reveals profiles of organ specificity and treatment resistance. Clinical Cancer Research. 2021;27(7):2074\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3752\/78985\/AM\/CLINICAL-PROTEOMICS-OF-METASTATIC-MELANOMA-REVEALS. PMID: 33446566.","DOI":"10.1158\/1078-0432.CCR-20-3752\/78985\/AM\/CLINICAL-PROTEOMICS-OF-METASTATIC-MELANOMA-REVEALS"},{"key":"3734_CR74","doi-asserted-by":"publisher","unstructured":"Ellebaek E, Khan S, Bastholt L, Schmidt H, Haslund CA, Donia M et al. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. Eur J Cancer. 2024;198. https:\/\/doi.org\/10.1016\/j.ejca.2023.113476. PMID: 38171116.","DOI":"10.1016\/j.ejca.2023.113476"},{"key":"3734_CR75","doi-asserted-by":"publisher","unstructured":"Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022;126(12):1663\u201375. https:\/\/doi.org\/10.1038\/S41416-022-01743-4. PMID: 35228677.","DOI":"10.1038\/S41416-022-01743-4"},{"key":"3734_CR76","doi-asserted-by":"publisher","unstructured":"Gajjela BK, Zhou MM. Bromodomain inhibitors and therapeutic applications. Curr Opin Chem Biol. 2023;75. https:\/\/doi.org\/10.1016\/j.cbpa.2023.102323. PMID: 37207401.","DOI":"10.1016\/j.cbpa.2023.102323"},{"key":"3734_CR77","doi-asserted-by":"publisher","unstructured":"Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE et al. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019;9(5):628\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1489. PMID: 30787016.","DOI":"10.1158\/2159-8290.CD-18-1489"},{"key":"3734_CR78","doi-asserted-by":"publisher","unstructured":"Zaidi MR. The Interferon-Gamma Paradox in Cancer. J Interferon Cytokine Res. 2019;39(1):30\u20138. https:\/\/doi.org\/10.1089\/JIR.2018.0087. PMID: 30388040.","DOI":"10.1089\/JIR.2018.0087"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03734-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:11:37Z","timestamp":1784164297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03734-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3734"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03734-2","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The authors found a color error in the published version of Figure 7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study on paraffin-embedded (FFPE) samples of MCM, collected from patients diagnosed and treated from 2010 to 2019 at Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, was conducted in accordance with ethical standards, having received approval from the Local Ethics Committee (16275_bio) under the principles outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and consent to this publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}